Mahajna, H
14  Ergebnisse:
Personensuche X
?
1

P510 Relapse rate following withdrawal of vedolizumab and u..:

Albshesh, A ; Kucha, P ; Mahajna, H...
Journal of Crohn's and Colitis.  18 (2024)  Supplement_1 - p. i1009-i1010 , 2024
 
?
2

P676 Intestinal ultrasound accurately predicts therapy fail..:

Albshesh, A ; Abend, A ; Margalit Yehuda, R...
Journal of Crohn's and Colitis.  17 (2023)  Supplement_1 - p. i808-i808 , 2023
 
?
3

P623 The effectiveness and tolerability of Crohn's disease ..:

Mahajna, H ; Abu-Salah, R ; Tzur, M...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i547-i548 , 2022
 
?
4

P647 Idiopathic Thrombocytopenic Purpura associated with In..:

Mahajna, H ; Verstockt, B ; Bergemalm, D...
Journal of Crohn's and Colitis.  16 (2022)  Supplement_1 - p. i561-i561 , 2022
 
?
5

P402 Prediction of emergency department re-visit among Croh..:

Mahajna, H ; Barash, Y ; Ungar, B...
Journal of Crohn's and Colitis.  14 (2020)  Supplement_1 - p. S372-S372 , 2020
 
?
6

Immune-Mediated Disease Flares or New-Onset Disease in 27 S..:

Watad, A ; De Marco, G ; Mahajna, H...
https://eprints.whiterose.ac.uk/174158/6/vaccines-09-00435-v2.pdf.  , 2021
 
?
7

Contributors:

, In: Infection and Autoimmunity,
 
?
 
?
10

794: Crizotinib is an allosteric ABL-inhibitor targeting bo..:

Mahajna, J. ; Khamaisie, H. ; Ruimi, N....
European Journal of Cancer.  50 (2014)  - p. S191-S192 , 2014
 
?
 
?
12

5PSQ-100 The appropriateness of hypophosphataemia treatment..:

Amarney, K ; Mahajna, M ; Kab, H.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7535300/.  , 2018
 
1-14